NCT00586885已完成不适用
A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis
Keith D Lindor, M.D.1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2004年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- To assess the safety and tolerability of long-term L-alanine supplementation and the therapeutic efficacy of long-term L-alanine supplementation by evaluating liver biochemistry and histological findings.
研究概览
简要总结
Purpose of this study is to assess the therapeutic efficacy of L-alanine in improving biological and histological findings by administrating 6-18g/day L-alanine for one year. We will also assess the safety and toxicity profile of long-term administration of L-alanine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, age between 18 and 75
- •Histological diagnosis of steatohepatitis with or without fibrosis made within one year of entry
- •Transaminase levels (ALT or AST) more than 1.5 times the upper normal limit on at least two occasions with one assessment in three months or more prior to treatment of this study
- •Previous and current alcohol consumption less than 20g per day by patient-provided information.
- •Written informed consent specific for this protocol available prior to entry.
- •Patients with diabetes and on stable medical management for six months prior to entry and an anticipated stable program throughout the study will be eligible. Medications that may be used include insulin, biguanides and sulfonylureas.
- •Patients with congestive heart failure, hypertension and arrhythmia controlled by medications and without cardiac episodes during the past 6 months will be eligible.
排除标准
- •Any causes for liver disease other than nonalcoholic steatohepatitis that are confirmed by patient history, laboratory data, or histological data
- •Decompensated liver disease based on laboratory data, or clinical manifestations
- •Hemoglobin <11.0g/dl for male, <10.0 g/dl for female
- •White blood cells <2000 /mm3
- •Platelet count <50,000/mm3
- •Prothrombin time >INR 1.5
- •Total Bilirubin >2.0 g/dl
- •Albumin <3.0/dl
- •The presence of ascites
- •The presence of bleeding varices
- •The presence of spontaneous encephalopathy
- •Any previous experimental treatment of NASH within the past 3 months such as betaine, thiazolidinediones, α-tocopherol, or UDCA
- •Pre-existing diseases/situations that could interfere with the results or the completion of this trial.
- •Uncontrolled diabetes mellitus meeting following criteria in previous 3 months
- •Fasting blood sugar >200 mg/dl
- •Hemoglobin A1c >12%
- •Renal or liver transplant patients
- •Renal dysfunction in previous 3 months
- •a) CCr <50ml/min
- •Severe cardiovascular dysfunction in previous 6 months
- •Congestive heart failure
- •Uncontrolled hypertension
- •Uncontrolled arrhythmia
- •Patients with hyperlipidemia on a medical program for control of lipids which has had a change in drug treatment in the proceeding six months or with anticipated changes in the year of the study.
- •Chronic pulmonary disease such as COPD requiring corticosteroid therapy in previous 3 months
- •Active autoimmune or immunologically mediated diseases including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel diseases in previous 12 months
- •Previous (in three years) or present malignant disease except for non-melanoma skin cancer
- •Untreated hyperthyroidism and hypothyroidism
- •Substance abuse of oral, I.V., or inhaled drugs.
- •If patients with history of substance abuse are considered as participants in this trial, patients must have abstained from using the abused substance for at least one year.
- •Patients receiving methadone within the past 6 months are also excluded.
- •Any other conditions that would make the patients unsuitable for enrollment in the opinion of the investigator in terms of interference in completing the trial and/or results of trial.
- •Pregnant women
- •Unwillingness of patients and /or partner to use contraceptive during treatment and for 3 months after discontinuation of treatment.
研究组 & 干预措施
1
Experimental
Single arm, active treatment
干预措施: L-alanine (Drug)
结局指标
主要结局
To assess the safety and tolerability of long-term L-alanine supplementation and the therapeutic efficacy of long-term L-alanine supplementation by evaluating liver biochemistry and histological findings.
时间窗: 1 year
次要结局
- Determine the effect of L-alanine on gene profiles, anti-oxidant response and inflammatory response in hepatocytes. Evaluate possible correlation between therapeutic efficacy and gene profiles altered by L-alanine supplementation(1 year)
研究者
Keith D Lindor, M.D.
Medical Doctor
Mayo Clinic
研究点 (1)
Loading locations...
相似试验
已完成
4 期
L-Arginine and Erectile DysfunctionErectile DysfunctionNCT00777075Hannover Medical School57
终止
4 期
Effect of Chronic Supplementation of L-arginine in the Muscular PerformanceMuscular FatigueNCT00785811Sanofi36
已完成
不适用
Effect of L-alanyl L-glutamine dipeptide on diarrhea, treatment response, and patients’ survival in colon cancer patients receiving chemotherapyIncidence of diarrhea in colon cancer patients receiving mFOLFOX-6 therapySigns and SymptomsISRCTN13489936Taif University44
终止
2 期
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile InfectionClostridium Difficile InfectionNCT02053350University of Virginia7
终止
2 期
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain TumorsMalignant GliomaGlioblastomaGliomaGlioblastoma MultiformeAstrocytomaNCT01351519MultiCare Health System Research Institute16